ANI Pharmaceuticals (NASDAQ:ANIP) Raised to Strong-Buy at Leerink Partnrs

ANI Pharmaceuticals (NASDAQ:ANIP) was upgraded by investment analysts at Leerink Partnrs to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

A number of other research analysts also recently issued reports on the stock. Raymond James raised their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target on the stock. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday. They issued an “outperform” rating and a $80.00 price target on the stock. Finally, Truist Financial raised their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Trading Down 4.4 %

NASDAQ ANIP opened at $56.56 on Wednesday. ANI Pharmaceuticals has a 12 month low of $51.24 and a 12 month high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -102.84 and a beta of 0.73. The company’s fifty day moving average price is $58.04 and its two-hundred day moving average price is $60.36.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same period in the prior year, the firm posted $1.05 EPS. The firm’s revenue was up 12.5% compared to the same quarter last year. As a group, research analysts predict that ANI Pharmaceuticals will post 3.87 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,731 shares of company stock worth $2,015,861 in the last ninety days. 12.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Texas Permanent School Fund Corp grew its stake in shares of ANI Pharmaceuticals by 1.3% in the 2nd quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock worth $852,000 after purchasing an additional 178 shares during the last quarter. Louisiana State Employees Retirement System grew its stake in shares of ANI Pharmaceuticals by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after purchasing an additional 200 shares during the last quarter. Arizona State Retirement System grew its stake in shares of ANI Pharmaceuticals by 4.7% in the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 211 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares during the last quarter. Finally, New York State Teachers Retirement System grew its stake in shares of ANI Pharmaceuticals by 1.7% in the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after purchasing an additional 394 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.